Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1546]

The use of genomic sequencing panels to personalise cancer treatment is beneficial in only 5% of the patients in whom they are currently used

The use of genomic sequencing panels to personalise cancer treatment is beneficial in only 5% of the patients in...

Some breast cancer treatments may limit effectiveness of weight loss medications

Some breast cancer treatments may limit effectiveness of weight loss medications

Further hope for base-edited T-cell therapy to treat resistant leukaemia

Further hope for base-edited T-cell therapy to treat resistant leukaemia

NCCN launches roadmap for improving thyroid cancer care in LMICs

NCCN launches roadmap for improving thyroid cancer care in LMICs

Cancer has an obesity-related risk factor and it depends on sex and cancer type

Cancer has an obesity-related risk factor and it depends on sex and cancer type

First randomised controlled trial of genetic counselling for familial and inherited colorectal cancer shows significant improvements in patient empowerment

First randomised controlled trial of genetic counselling for familial and inherited colorectal cancer shows...

ASCO 2023: Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer

ASCO 2023: Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced...

ASCO 2023: Study may provide clues to treating colorectal cancer more effectively in younger patients

ASCO 2023: Study may provide clues to treating colorectal cancer more effectively in younger patients

ASCO 2023: Targeted therapy induces responses in HER2-amplified biliary tract cancer

ASCO 2023: Targeted therapy induces responses in HER2-amplified biliary tract cancer

ASCO 2023: Addition of olaparib and durvalumab prolonged progression-free survival in patients with advanced ovarian cancer

ASCO 2023: Addition of olaparib and durvalumab prolonged progression-free survival in patients with advanced...

More from ecancer